| 1 |
Minaei N, Ramezankhani R, Tamimi A, Piryaei A, Zarrabi A, Aref AR, Mostafavi E, Vosough M. Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future. Eur J Cell Biol 2023;102:151284. [PMID: 36584598 DOI: 10.1016/j.ejcb.2022.151284] [Reference Citation Analysis]
|
| 2 |
Li T, Liu Z, Fu X, Chen Y, Zhu S, Zhang J. Co-delivery of Interleukin-12 and Doxorubicin Loaded Nano-delivery System for Enhanced Immunotherapy with Polarization toward M1-type Macrophages. Eur J Pharm Biopharm 2022:S0939-6411(22)00140-0. [PMID: 35811038 DOI: 10.1016/j.ejpb.2022.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Zeng C, Zhang L, Luo C, Yang C, Huang X, Fan L, Li J, Chen F, Luo Z. A stratification model of hepatocellular carcinoma based on expression profiles of cells in the tumor microenvironment. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09647-5] [Reference Citation Analysis]
|
| 4 |
Feng L, Jing F, Qin X, Zhou L, Ning Y, Hou J, Kong W, Zhu Y. Cleavage Stimulation Factor Subunit 2: Function Across Cancers and Potential Target for Chemotherapeutic Drugs. Front Pharmacol 2022;13:852469. [DOI: 10.3389/fphar.2022.852469] [Reference Citation Analysis]
|
| 5 |
Peng Q, Zhou Y, Oyang L, Wu N, Tang Y, Su M, Luo X, Wang Y, Sheng X, Ma J, Liao Q. Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics. Mol Ther 2022;30:1018-35. [PMID: 34793975 DOI: 10.1016/j.ymthe.2021.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 6 |
Li H, Qin S, Liu Y, Chen Z, Ren Z, Xiong J, Meng Z, Zhang X, Wang L, Zhang X, Zou J. Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. Drug Des Devel Ther 2021;15:1873-82. [PMID: 33976538 DOI: 10.2147/DDDT.S304857] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 7 |
Zeng Z, Yang B, Liao Z. Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors. Front Oncol 2021;11:650481. [PMID: 33777812 DOI: 10.3389/fonc.2021.650481] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 8 |
Yin L, Zhou L, Xu R. Identification of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma Based on Multi-Omics Analysis. Front Mol Biosci 2020;7:599142. [PMID: 33681288 DOI: 10.3389/fmolb.2020.599142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 9 |
Feng GS, Hanley KL, Liang Y, Lin X. Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies. Hepatology 2021;73 Suppl 1:104-14. [PMID: 32715491 DOI: 10.1002/hep.31479] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 10 |
Wang Q, Huang J, Zhang H, Liu H, Yu M. Identification and analysis of immune-related subtypes of hepatocellular carcinoma. Exp Biol Med (Maywood) 2021;246:667-77. [PMID: 33231514 DOI: 10.1177/1535370220970130] [Reference Citation Analysis]
|
| 11 |
Wang L, Yang Z, Cao Y. Regulatory T cell and activated natural killer cell infiltration in hepatocellular carcinoma: immune cell profiling using the CIBERSORT. Ann Transl Med 2020;8:1483. [PMID: 33313228 DOI: 10.21037/atm-20-5830] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 12 |
Zhang Y, Yang Y, Ye J, Gao Y, Liao H, Zhou J, Feng Y, Liu D, Meng Y, Chen X, Gao L, Liu Y. Construction of chlorogenic acid-containing liposomes with prolonged antitumor immunity based on T cell regulation. Sci China Life Sci 2021;64:1097-115. [PMID: 33009993 DOI: 10.1007/s11427-020-1739-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 13 |
Fan C, Zhang S, Gong Z, Li X, Xiang B, Deng H, Zhou M, Li G, Li Y, Xiong W, Zeng Z, Li X. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy. Sci China Life Sci 2021;64:534-47. [PMID: 32815067 DOI: 10.1007/s11427-019-1735-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 14 |
Zeng Z, Yang B, Liao ZY. Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma. Oncol Lett 2020;20:45. [PMID: 32802167 DOI: 10.3892/ol.2020.11909] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 15 |
Cui X, Liu Y, Sun W, Ding J, Bo X, Wang H. Comprehensive analysis of miRNA-gene regulatory network with clinical significance in human cancers. Sci China Life Sci 2020;63:1201-12. [PMID: 32170623 DOI: 10.1007/s11427-019-9667-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 16 |
Wang Y, Bao Y, Zhang S, Wang Z. Splicing dysregulation in cancer: from mechanistic understanding to a new class of therapeutic targets. Sci China Life Sci 2020;63:469-84. [PMID: 32086672 DOI: 10.1007/s11427-019-1605-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 17 |
Zhao Z, Xiao X, Saw PE, Wu W, Huang H, Chen J, Nie Y. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Sci China Life Sci 2020;63:180-205. [PMID: 31883066 DOI: 10.1007/s11427-019-9665-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
|
